Posted on 07/31/2006 9:04:20 PM PDT by MainFrame65
Developed by Pfizer, pregabalin, marketed under the brand name Lyrica, is a 3-substituted analogue of gamma-amino butyric acid (GABA) and a compound related to Pfizer's hugely successful antiepileptic drug gabapentin (Neurontin).
In July 2004, Pfizer secured Europe-wide approval for Lyrica (pregabalin) for use in the management of peripheral neuropathic pain as well as an adjunctive therapy in the treatment of partial epileptic seizures. Subsequently in December 2004 the company gained FDA approval for use of Lyrica (pregabalin) in neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia; making it the first FDA-approved treatment for both of these neuropathic pain states. Lyrica (pregabalin) is also being reviewed by the FDA as an adjunctive treatment for partial epileptic seizures in adults. A SUCCESSOR TO GABAPENTIN
First marketed in 1983, gabapentin (Neurontin) has been one of Pfizer's top performing drugs. Lyrica (pregabalin) is seen as an important successor now that gabapentin is facing the threat of generic competition.
Both drugs share a similar mechanism of action: binding to calcium channels and modulating calcium influx as well as influencing GABergic neurotransmission. This mode of action translates into anti-epileptic, analgesic and anxiolytic effects. Because it is more potent than gabapentin, Lyrica (pregabalin) achieves efficacy at lower doses. This increases its therapeutic index with respect to gabapentin and should lead to fewer dose-related side effects. Clinical studies with Lyrica (pregabalin) have been carried out on over 10,000 patients worldwide. CLINICAL STUDIES WITH LYRICA (PREGABALIN) IN EPILEPSY
Gabapentin is approved worldwide for adjunctive treatment of patients with partial epilepsy. Because it is not metabolised (and so does not alter the pharmacokinetics of co-administrated drugs) it is a good candidate for use in combination with other antiepileptic medications. Clinical studies with oral Lyrica (pregabalin) suggest it is at least as effective as gabapentin as adjunctive therapy in patients refractory to one or more conventional antiepileptic drugs. In large-scale, placebo-controlled studies of 12 weeks' duration, add-on therapy with oral Lyrica (pregabalin) reduced seizure frequency by up to 75%. In these studies doses of Lyrica (pregabalin) ranged from 150mg to 600mg daily. CLINICAL STUDIES WITH LYRICA (PREGABALIN) IN NEUROPATHIC PAIN AND ANXIETY DISORDER
Neuropathic pain is chronic pain that arises from damage to sensory nerves. It can include:
* Pain arising from trapped or compressed nerves * Drug-induced nerve damage * Diabetic neuropathy * Post-herpetic pain * Phantom limb syndrome following limb amputation * Peripheral neuropathy * Fibromyalgia
Neuropathic pain generally does not respond to treatment with opioid or non-steroidal anti-inflammatory drugs (NSAIDs). At high doses gabapentin has proven effective against neuropathic pain induced by diabetic neuropathy and postherpetic neuralgia. Data from clinical studies show that Lyrica (pregabalin) shares this analgesic effectiveness. Efficacy has been demonstrated in a number of clinical studies, including those in patients with diabetic neuropathy and fibromyalgia. Treatment of neuropathic pain is seen as the drug's leading indication.
A double-blind, placebo-controlled monotherapy study in 529 patients with fibromyalgia, for example, showed that eight weeks' treatment with Lyrica (pregabalin) 150mg to 450mg per day produced significantly greater reductions in pain compared with placebo as well as improving sleep quality and fatigue. Pain, sleep disturbances and fatigue are core symptoms of fibromyalgia, which has proved an extremely difficult condition to treat.
Data from a series of phase II and III placebo-controlled clinical studies in over 1,200 patients with generalised anxiety disorder suggest that Lyrica (pregabalin) will be effective for this disabling disorder. In comparison with venlafaxine, pregabalin provided more rapid relief of psychic and somatic symptoms. In comparison with alprazolam (a benzodiazepine), Lyrica (pregabalin) appeared equally effective in reducing somatic symptoms. Overall, these findings show that Lyrica (pregabalin) combines the benefits of both antidepressants and benzodiazepines. It appears at least as rapid as benzodiazepines against somatic symptoms, while providing more rapid control of psychic symptoms than antidepressants.
MARKETING COMMENTARY
Once generic manufacture of gabapentin is approved, sales of Pfizer's Neurontin are likely to fall dramatically. Encouraging physicians to switch patients from Neurontin to Lyrica (pregabalin), if approved, will be an important strategy in minimising the impact of generic competition. Lyrica (pregabalin) is as effective as Neurontin, but at lower doses, which translates to fewer side effects. Thus, it is well placed to capture Neurontin's market share. Through the successful launch of follow-on products, Pfizer has maintained leadership in other CNS areas, such as the market for antidepressants.
In one week on Lyrica, I am actually recovering some sensation in both feet. So far, they mostly just tingle and feel hot or cold, but I am beginning to have a better sense of their position and location.
glad to hear it....hope you continue to improve....
Thanks for posting.
Anyway, good luck w/your treatment. Let's hope this new stuff works.
You had me at pregabalin. Seriously though, good luck w/your treatment.
Lyrica? Hope it works as anticipated. As a tenor, I am tempted to take it just because of the name.
Cousin Vinnie
Wish this was available when I contracted shingles (at the ripe "old" age of 32... stress at work was a killer and my imune system failed... I hate when that happens.
Lyrica made me so addled and made it very difficult to think that I had to stop taking it.
I am glad that it works for you, however.
I have found it to be a very effective drug for many of my patients.
LYRICA (PREGABALIN) - NEW GABAPENTINOID WITH WIDE CLINICAL APPLICATION
You had me at pregabalin. Seriously though, good luck w/your treatment.
LOL - me too. I may be kolege edukatid but the title is way over my head.
pfizer paid $400m fine for detailing physicians on Neurontin on pain (several years ago), as it did not have FDA approved indication for pain at the time (it was originally developed as anti-seizure med and did have FDA approval ). Later, Neurontin did get the FDA indication for neuropathic pain after proving itself in clinical trials. It is actually quite effective in many cases ( I think it's in top 10 of all prescriptions written). As patent was expiring on Neurontin, Pfizer developed Lyrica, but according to this testimonial and others it is more than just a marketing ploy to extend the profitability (e.g. Nexium for Prilosec, Paxil CR for Paxil, etc., etc.) Too bad TV networks don't have to pay multimillion dollars fines for some of the false info they put out; it might force them to clean up their acts too.
Disclaimer: Opinions posted on Free Republic are those of the individual posters and do not necessarily represent the opinion of Free Republic or its management. All materials posted herein are protected by copyright law and the exemption for fair use of copyrighted works.